{"ticker": {"uuid": "fb7a4948-aa80-4e65-aa8e-6e4c41924459", "symbol": "AGY", "name": "Allergy Therapeutics plc", "exchange": "LSE", "country": "GB", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Price to sales forward of Allergy Therapeutics plc \u2013 LSE:AGY", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRUxwOHU2YUd5dElyNFpNeWJrZU5CUDdhZTlhVFFCQkxwOWFSOVRKWmpWSVR6MGliZ2pnTGVET3VuY2pxaDM2MmMxVHR1bDNCM3ppUzlwUVY2ekhnMmtfNC1BWm5VQ01qdmxvc1BkRzU2WmF2MVhqT1dpT094TjRWX2xBYlRNUmt1YWpFY0Y1Y0hWTWhjcUM4SQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-08T05:19:01+00:00", "published_display": "08 Jul 2026 05:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allergy Therapeutics peanut vaccine shows strong immune response in early trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPV3lBREEzVzRZeldkX2s1c0hUZ1JpQnZxT1pZZVh2WW9uSmN3UGprQXpmdjBiR1BtdjA4REJtSm9wQlRjSXZkRUY1UlFCVnJYQURzM3hIQUgwbEd4QTJRWnpVRElTM3gxRFc4LU4ycUI1WmxSam84THRpNEVSMTBrTHJ0TnJYVVNsdjVrMG9GLWZnZEM4?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "While shareholders of Allergy Therapeutics (LON:AGY) are in the black over 3 years, those who bought a week ago aren't so fortunate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allergy Therapeutics Shares Positive Data At The 2022 WAO-BSACI Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSm9CWV9HeE1lcFhmd0lRYXBwRk9feFRDa3VhTVhiZnlnTXBkcVJtMWd5MDBsVC1wdWxGazFNVDAxbTc1UlY3Y1dUdU9FeTVkMkNxV09ZWUJyTDFjazk3Y2N4SXZFWjl1c0x4UXZBWlVVdDFzY0VXQS1qR3M2UTZWY0drWGk5Tm5uYzFUNGNCZE1YNnZ2UzZKR0pqaUF2WUY5VVVRd2ZBTjRZb092YU9rZnc3U29VWGxUaVphUjlXdUdUTm8?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2022-04-25T07:00:00+00:00", "published_display": "25 Apr 2022 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE05WktmcnhuVng2czBvV2dxNkxCNmdMbjRCbmIzWnh3cURCcksweS02ek1GbDZaOVlxaDlZWjNXbWJSRkdqdnhDd0RtWHcydklWSGxQQmpfUDN1SDNHT1ozRmNwUzlQYjBMUVIxNnZHUklnS3BMdHdmTG9fdw?oc=5", "source_name": "Labiotech.eu", "published_at": "2019-03-18T07:00:00+00:00", "published_display": "18 Mar 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Numis Securities", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "marketexclusive.com", "published_at": "2018-09-26T07:00:00+00:00", "published_display": "26 Sep 2018 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SMALL CAP SHARE IDEAS: New funding drives Allergy Therapeutics towards a potential breakthrough in the US market", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "This is Money", "published_at": "2015-04-13T07:00:00+00:00", "published_display": "13 Apr 2015 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to sales forward of Allergy Therapeutics plc \u2013 LSE:AGY", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRUxwOHU2YUd5dElyNFpNeWJrZU5CUDdhZTlhVFFCQkxwOWFSOVRKWmpWSVR6MGliZ2pnTGVET3VuY2pxaDM2MmMxVHR1bDNCM3ppUzlwUVY2ekhnMmtfNC1BWm5VQ01qdmxvc1BkRzU2WmF2MVhqT1dpT094TjRWX2xBYlRNUmt1YWpFY0Y1Y0hWTWhjcUM4SQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-08T05:19:01+00:00", "published_display": "08 Jul 2026 05:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allergy Therapeutics peanut vaccine shows strong immune response in early trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPV3lBREEzVzRZeldkX2s1c0hUZ1JpQnZxT1pZZVh2WW9uSmN3UGprQXpmdjBiR1BtdjA4REJtSm9wQlRjSXZkRUY1UlFCVnJYQURzM3hIQUgwbEd4QTJRWnpVRElTM3gxRFc4LU4ycUI1WmxSam84THRpNEVSMTBrTHJ0TnJYVVNsdjVrMG9GLWZnZEM4?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "While shareholders of Allergy Therapeutics (LON:AGY) are in the black over 3 years, those who bought a week ago aren't so fortunate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNQVF1cDl4alRlcGhVS2MwTHlVWTZWNnVucERIdUJzdkpvTGVRSmpzSkZOdkVOb2psRjVTR3F4a0MzUWtQbDl6a2tlWjRJNVRrTnNWdDZoM0pzRlgyTUZ2UTYyRGdzZVVfU3MxOExIVnlWMk9fVEkxcmt3VnZqRGJ4T1k3OUlRcEQ4cjRxdnQ1ZEVfR1BLa0NISG1qcGZoWVgzbGFFdnZQb3ZETHkwYkM5MWtCR2Z1WDVETFNBWWE5c2xLbEYzdG5HNlQwenJwT0NmdWpSNGFPM3VnbjMtNFJyTnlDcEtWQk01Q3BfWGJB0gHzAUFVX3lxTFBwblBGeV9yd0J3djVMbGU4MGFlY3R0d3pqOTEzclFTQ1lScWdlOTVVa3ViTF9pM3hJeEhrVGNLVjZVYUV4QWVEZjRKZkI2YWVEelFxT2MwSklTWUczY3dkc2V2X21WU3Vjc05sbVRUQ2xoMGc1Yk9jbV9HOUp2Mkp1aGhzQzBWR0ptb3ZabTVDSkNZUnM4dHJPX1otLTRvUzBFOVdjSkhhQkNZLWU5eWdCUlNsNFNPdHBtNnhGR0FjWVRkWlY0V09LbzhWa01CbDQtSWRUckNMZVFOczltT0RlcERnSnNyR1pVdk1SbHZLMUgwWQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allergy Therapeutics Shares Positive Data At The 2022 WAO-BSACI Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSm9CWV9HeE1lcFhmd0lRYXBwRk9feFRDa3VhTVhiZnlnTXBkcVJtMWd5MDBsVC1wdWxGazFNVDAxbTc1UlY3Y1dUdU9FeTVkMkNxV09ZWUJyTDFjazk3Y2N4SXZFWjl1c0x4UXZBWlVVdDFzY0VXQS1qR3M2UTZWY0drWGk5Tm5uYzFUNGNCZE1YNnZ2UzZKR0pqaUF2WUY5VVVRd2ZBTjRZb092YU9rZnc3U29VWGxUaVphUjlXdUdUTm8?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2022-04-25T07:00:00+00:00", "published_display": "25 Apr 2022 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE05WktmcnhuVng2czBvV2dxNkxCNmdMbjRCbmIzWnh3cURCcksweS02ek1GbDZaOVlxaDlZWjNXbWJSRkdqdnhDd0RtWHcydklWSGxQQmpfUDN1SDNHT1ozRmNwUzlQYjBMUVIxNnZHUklnS3BMdHdmTG9fdw?oc=5", "source_name": "Labiotech.eu", "published_at": "2019-03-18T07:00:00+00:00", "published_display": "18 Mar 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Numis Securities", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "marketexclusive.com", "published_at": "2018-09-26T07:00:00+00:00", "published_display": "26 Sep 2018 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SMALL CAP SHARE IDEAS: New funding drives Allergy Therapeutics towards a potential breakthrough in the US market", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "This is Money", "published_at": "2015-04-13T07:00:00+00:00", "published_display": "13 Apr 2015 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 62, "total_relevant": 7, "sentiment_summary": {"positive": 3, "negative": 0, "neutral": 4, "score": 57, "total": 7, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.07, "latest_week": "2026-07-10", "one_week_move": 1.8, "four_week_move": -14.9, "twelve_week_move": -36.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.476001, "market_dynamics_buy_signal": false, "relative_strength": -33.106066, "fair_value_gap": 9.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 43.0839, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.8% over one week, -14.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 1}, {"label": "Market source", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "DirectorsTalk Interviews", "count": 1}, {"label": "Labiotech.eu", "count": 1}, {"label": "marketexclusive.com", "count": 1}, {"label": "This is Money", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 7}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 6}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "7", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.8% over one week, -14.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to sales forward of Allergy Therapeutics plc \u2013 LSE:AGY"}], "updated_at": "2026-07-18T01:47:29.407527+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}